Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
In summary, the dual inhibition of GPX4 and BCR-ABL presents a promising therapeutic strategy to synergistically target blast cells and drug-insensitive LSCs in patients, offering potential avenues for advancing leukemia treatment.
Authors
- Weizhang Wang (ORCID: https://orcid.org/0000-0001-8955-3135)
- Shuxin Zhong (ORCID: https://orcid.org/0009-0006-1758-2870)
- Cunte Chen (ORCID: https://orcid.org/0000-0003-3733-9174)
- Dingrui Nie (ORCID: https://orcid.org/0000-0001-5185-344X)
- Chengwu Zeng (ORCID: https://orcid.org/0000-0002-1333-3918)
- Wenyi Zhang (ORCID: https://orcid.org/0009-0006-9885-411X)
- Xianfeng Zha (ORCID: https://orcid.org/0000-0002-4970-1305)
- Yangqiu Li (ORCID: https://orcid.org/0000-0002-0974-4036)
- Xianfeng Wang (ORCID: https://orcid.org/0000-0001-7207-7865)
- Zhenhua Chen (ORCID: https://orcid.org/0000-0002-5195-2234)
- Xin Liu (ORCID: https://orcid.org/0000-0002-8843-9610)
- Xinyue Peng (ORCID: https://orcid.org/0000-0001-6386-2140)
- Xiangbo Zeng (ORCID: https://orcid.org/0000-0002-9740-9229)
- Kangjie Qiu
- Shengting Chen
Institutions
- Jinan University (CN)
- Guangdong Pharmaceutical University (CN)
- City of Hope (US)
- Guangzhou First People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- First Affiliated Hospital of Jinan University (CN)
- Beckman Research Institute
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s12943-024-02162-0
- Citations
- 33
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.99
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province